15 articles with Takeda Pharmaceuticals
London, UK, 3 June 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, announces the appointment of Stefan König as Chief Executive Officer.
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
Takeda’s non-small cell lung cancer treatment Mobocertinib is leading closer to regulatory approval after the U.S. Food and Drug Administration granted priority review to the New Drug Application.
Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]
In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC (Prime) has finalized an arrangement with Takeda Pharmaceutica
Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn's Disease Management
Takeda Pharmaceuticals U.S.A. (TSE: 4502) (NYSE:TAK) ("Takeda") and MiTest Health LLC ("MiTest"), a pioneering health technology company, today announced an exclusive partnership to optimize MiTest's personalized risk and outcome prediction tool for widespread use in patients with Crohn's disease (CD).
First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda's Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints
Positive findings on clinical endpoints for Budesonide Oral Suspension (BOS) presented during ACG 2019 Presidential Plenary Session
EIP Pharma, Inc. a CNS-focused therapeutics company, announced that it has expanded its leadership team with the appointment of Noel Donnelly as CFO. Mr. Donnelly joins EIP Pharma from Takeda Pharmaceuticals where he led a group focused on strategy and operations.
Takeda Pharmaceutical Company Limited became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment.
Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health"
Takeda Pharmaceutical Company Limited and the London School of Hygiene & Tropical Medicine will announce at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM.
Takeda to Highlight New Research into the Long-term Complications of Chronic Hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting
Seven presentations will be shared, including new data on the risks of long-term cardiovascular, renal and infection complications, underlining Takeda’s commitment to further understanding of this rare disease
Takeda Pharmaceutical Company Limited announced that it has entered into agreements to divest its Xiidra® 5% product to Novartis and its TachoSil® Fibrin Sealant Patch to Ethicon as part of its strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.
Sixth pharma partner to internalize the Adimab platform
LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology
Takeda gains certain rights to LCB’s antibody-drug conjugate technology, ConjuAll, including LCB’s proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics.
Fears Nachawati Investigating Possible Uloric Lawsuits After FDA Issues Strongest Warning for Gout Drug
FDA orders boxed warning on packaging after studies confirm death risks